Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies
暂无分享,去创建一个
P. Spellman | G. Mills | K. Chin | J. Gray | J. Goecks | L. Coussens | C. Corless | Y. Chang | R. Bergan | A. Guimaraes | M. Labrie | J. Vuky | Brett E. Johnson | J. Keck | K. Siex | A. Kolodzie | S. Parmar | Allen Li | A. Blucher | J. Lim | C. Boniface | C. Betts | S. Sivagnanam | Jamie M. Keck | Z. Mitri | A. Creason | Hongli Ma | Lina Gao | M. Downey | Kiara Siex | Molly Downey | Shamilene Sivagnanam | Zahi I. Mitri | Swapnil Parmar | Jeremy Goecks | J. Gray
[1] E. Winer,et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[2] A. Italiano,et al. Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC) , 2019, Annals of Oncology.
[3] S. Loi,et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. , 2017, The New England journal of medicine.
[4] G. Mills,et al. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. , 2019, Cancer cell.
[5] G. Mills,et al. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options , 2019, Oncotarget.
[6] G. Mills,et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. , 2019, The Lancet. Oncology.
[7] B. Xu,et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] S. O'Reilly,et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. , 2019, The New England journal of medicine.
[9] S. Ramaswamy,et al. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models , 2019, Scientific Reports.
[10] A. Ashworth,et al. PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer , 2019, The Journal of clinical investigation.
[11] G. Mills,et al. Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness , 2019, Molecular Cancer Therapeutics.
[12] P. Fasching,et al. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO) , 2018, Clinical Cancer Research.
[13] G. Mills,et al. Implementing a comprehensive translational oncology platform: from molecular testing to actionability , 2018, Journal of Translational Medicine.
[14] G. Freeman,et al. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer , 2018, Cell reports.
[15] E. Winer,et al. Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.
[16] P. Elvin,et al. Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response , 2018, Molecular Cancer Therapeutics.
[17] Sean C. Bendall,et al. A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging , 2018, Cell.
[18] M. Robson,et al. Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases. , 2018 .
[19] G. Mills,et al. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. , 2018, Cancer research.
[20] Sandro Santagata,et al. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes , 2018, eLife.
[21] Gary Middleton,et al. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. , 2018, Cancer discovery.
[22] Jill A. Madden,et al. Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition , 2018, Molecular Cancer Research.
[23] G. Mills,et al. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. , 2018, Cancer cell.
[24] Y. Bang,et al. Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC) , 2018 .
[25] B. Elenbaas,et al. MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models , 2018, Oncotarget.
[26] A. Glas,et al. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting , 2017, Breast Cancer Research.
[27] D. Berry,et al. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial , 2017, npj Breast Cancer.
[28] M. Robson,et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.
[29] G. Mills,et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers , 2017, Science Translational Medicine.
[30] Wenjun Chang,et al. Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer , 2017, Science Signaling.
[31] Adam A. Margolin,et al. Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. , 2017, Cell reports.
[32] G. Hortobagyi,et al. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression , 2017, Clinical Cancer Research.
[33] James S. Duncan,et al. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. , 2017, Cancer discovery.
[34] G. Mills,et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] P. Sorger,et al. Cyclic Immunofluorescence (CycIF), A Highly Multiplexed Method for Single‐cell Imaging , 2016, Current protocols in chemical biology.
[36] J. Xu,et al. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer , 2016, International journal of biological sciences.
[37] Sanghui Park,et al. Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer. , 2016, Human pathology.
[38] James S. Duncan,et al. Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. , 2016, Cell reports.
[39] D. Lee,et al. Inhibition of Phospho-S6 Kinase, a Protein Involved in the Compensatory Adaptive Response, Increases the Efficacy of Paclitaxel in Reducing the Viability of Matrix-Attached Ovarian Cancer Cells , 2016, PloS one.
[40] Peter K. Sorger,et al. Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method , 2015, Nature Communications.
[41] Michael S. Goldberg,et al. The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer. , 2015, Biochemical and biophysical research communications.
[42] Gordon B Mills,et al. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer , 2014, Clinical Cancer Research.
[43] Sung-Won Kim,et al. A multi-institutional study of the prevalence of BRCA1 and BRCA2 large genomic rearrangements in familial breast cancer patients , 2014, BMC Cancer.
[44] Prahlad T. Ram,et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas , 2014, Nature Communications.
[45] E. Winer,et al. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. , 2013, European journal of cancer.
[46] P. Pandolfi,et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. , 2012, Cancer discovery.
[47] Lei He,et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. , 2012, Cancer discovery.
[48] L. Zitvogel,et al. The secret ally: immunostimulation by anticancer drugs , 2012, Nature Reviews Drug Discovery.
[49] Li Zhang,et al. Serial dilution curve: a new method for analysis of reverse phase protein array data , 2009, Bioinform..
[50] Luke Hughes-Davies,et al. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. , 2008, Neoplasia.
[51] G. Mills,et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.
[52] J. Goecks,et al. High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers. , 2020, Methods in enzymology.
[53] G. Mills,et al. Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance. , 2019, Advances in experimental medicine and biology.
[54] G. Mills,et al. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. , 2017, American journal of cancer research.